• Robust Balance Sheet to Execute Growth Strategies in 2022
  • Full Year 2022 Revenue Growth Outlook +10%

LAKE FOREST, Calif., March 17, 2022 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced its financial results for the fourth quarter and full year ended December 31, 2021.

BIOLASE Logo (PRNewsfoto/BIOLASE, Inc.)

2021 Fourth Quarter and Recent Highlights

  • Total revenue was 12.4 million, up 46% year over year
  • Total revenue also increased 22% over fourth quarter 2019 pre-COVID results
  • U.S. laser sales increased 39% year over year and U.S. consumable sales increased 40% year over year, driven by significantly increased procedures using BIOLASE lasers
  • International laser sales increased 87% year over year and international consumable sales increased 29% year over year, driven by significantly increased procedures using BIOLASE lasers
  • Higher average selling price and sales volumes resulted in 40% gross margin for the quarter, a significant improvement from a year ago
  • Continued momentum with new customers and dental specialists
  • FDA clearance received for the new EdgePRO laser, which was co-developed with EdgeEndo, a global leader in commercializing products for the endodontics market
  • Maintained robust balance sheet with cash and cash equivalents of $30.0 million on December 31, 2021

"Our strong fourth quarter and full year performance reflects the rising demand for our industry-leading dental lasers," commented John Beaver, President and Chief Executive Officer. "Furthermore, our robust balance sheet and continued business momentum allowed us to enter 2022 in a favorable position to achieve our operating objectives for the year.

"With only about 7% of the U.S. dental community currently using dental lasers, we are confident in our ability to drive further adoption of this new standard of care.  The positive clinical data published in 2021 on the use of dental lasers, combined with the launch of our specialist academies for endodontists, periodontists, pediatric dentists, and dental hygienists is generating increased adoption of laser technology.  These initiatives, along with the continued success of our Waterlase Exclusive Trial Programs and our further penetration into the DSO space, positions us for continued revenue growth in 2022.  With every one percentage point increase in market adoption of laser technology in the U.S. alone, we estimate it will generate an additional $50 million in revenue for BIOLASE, assuming we keep our same 60% market share."

2021 Fourth Quarter Financial Results

Net revenue for the fourth quarter of 2021 was $12.4 million, an increase of 46% year over year. Compared to the fourth quarter of 2019, which was the last full quarter prior to the impact of the COVID-19 pandemic, revenue increased 22% from $10.2 million. U.S. laser revenue was $5.3 million for the fourth quarter of 2021, up 39% when compared to U.S. laser revenue of $3.8 million for the fourth quarter of 2020. U.S. consumables and other revenue for the fourth quarter of 2021, which consists of revenue from consumable products such as disposable tips, increased 40% compared to the fourth quarter of 2020. Outside the U.S., laser revenue increased 87% to $3.1 million for the fourth quarter of 2021 compared to $1.7 million for the fourth quarter of 2020, and consumables and other revenue increased 29% year over year.

Gross margin for the fourth quarter of 2021 was 40%, compared to 19% for the fourth quarter of 2020. The higher gross margin reflects the increase in revenue relative to the Company's fixed costs as well as higher average U.S. selling prices of its lasers. Total operating expenses were $9.3 million for the fourth quarter of 2021 compared to $7.1 million for the fourth quarter of 2020. Operating loss for the fourth quarter of 2021 was $4.4 million, compared to an operating loss of $5.5 million in the fourth quarter of 2020.

Full Year 2021 Financial Results

Net revenue for the year ended December 31, 2021 was $39.2 million, an increase of 72% compared to net revenue of $22.8 million for the year ended December 31, 2020, and an increase of 4% compared to the net revenue of $37.8 million for the year ended December 31, 2019. U.S. laser revenue was $14.8 million for the year ended December 31, 2021, an increase of 77% compared to U.S. laser revenue of $8.3 million for the year ended December 31, 2020.  U.S. consumables and other revenue for the year ended December 31, 2021, which consists of revenue from consumable products such as disposable tips, increased 63% year over year. International laser revenue increased 155% to $10.3 million for the year ended December 31, 2021, compared to $4.0 million for the year ended December 31, 2020.

Gross margin for the year ended December 31, 2021 was 42% compared to 27% for the year ended December 31, 2020. Total operating expenses were $33.0 million for the year ended December 31, 2021, compared to $24.7 million for the year ended December 31, 2020, a 33% increase year over year.  Operating loss for the year ended December 31, 2021 was $16.4 million, compared to an operating loss of $18.5 million for the year ended December 31, 2020, a decrease of 11% year over year.

The Company maintained a robust balance sheet and had cash and cash equivalents of approximately $30.0 million on December 31, 2021.  The Company believes it has sufficient financial resources to execute its near and long-term growth strategies.

Net Loss and Adjusted EBITDA

The reconciliation of GAAP Net Loss to Adjusted EBITDA at the end of this news release provides the details of the Company's non-GAAP disclosures and the reconciliation of GAAP net loss and net loss per share to the Company's Adjusted EBITDA and Adjusted EBITDA per share.

Net loss for the fourth quarter of 2021 was $5.3 million, or $0.03 per share, compared to a net loss of $6.1 million, or $0.07 per share, for the fourth quarter of 2020. Adjusted EBITDA loss for the fourth quarter of 2021 was $4.3 million, or $0.03 per share, compared with Adjusted EBITDA loss of $4.5 million, or $0.05 per share, for the fourth quarter of 2020.

Net loss attributable to common stockholders for the year ended December 31, 2021 was $16.7 million, or $0.11 per share, compared to a net loss of $34.2 million, or $0.56 per share, for the year ended December 31, 2020. Adjusted EBITDA for the year ended December 31, 2021 was a loss of $14.7 million, or $0.10 per share, compared with an Adjusted EBITDA loss of $13.4 million, or $0.22 per share, for the year ended December 31, 2020. 

2022 First Quarter and Full Year Revenue Guidance

Based on currently available information and the continued operating momentum the Company has experienced so far this year, BIOLASE is anticipating first quarter net revenue to exceed $9.0 million, which would represent growth of at least 11% year over year.  The Company expects full year net revenue to increase at least 10% from 2021 levels.

Conference Call Information

BIOLASE, Inc. will host a conference call today at 4:30 p.m. Eastern Time to discuss its operating results for the fourth quarter and full year ended December 31, 2021 and to answer questions. For both "listen-only" participants and those participants who wish to take part in the question-and-answer portion of the call, the dial-in number in the U.S. and Canada is (888) 254-3590. For participants outside the U.S. and Canada, the dial-in number is +1 (323) 794-2551. For all callers, refer to the Conference ID 9127979.  To access the live webcast, visit the Investor Relations section of the BIOLASE website at www.biolase.com and see "Investor Events".

An audio archive of the webcast will be available for 30 days on the Investor Relations section of the BIOLASE website.

About BIOLASE

BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASE's products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE's proprietary laser products incorporate approximately 301 patented and 38 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASE's innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. BIOLASE has sold over 43,300 laser systems to date in over 80 countries around the world. Laser products under development address BIOLASE's core dental market and other adjacent medical and consumer applications.

For updates and information on Waterlase iPlus®, Waterlase Express™, and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Instagram at www.instagram.com/waterlase_laserdentistry, and LinkedIn at www.linkedin.com/company/biolase.

BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties, including statements, regarding BIOLASE's expected revenue and revenue growth during the first quarter of 2022, expected revenue growth during 2022 and beliefs regarding its financial resources. Forward-looking statements can be identified through the use of words such as may," "might," "will," "intend," "should," "could," "can," "would," "continue," "expect," "believe," "anticipate," "estimate," "predict," "outlook," "potential," "plan," "seek," and similar expressions and variations or the negatives of these terms or other comparable terminology. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE's current expectations and speak only as of the date of this release. Actual results may differ materially from BIOLASE's current expectations depending upon a number of factors. These factors include, among others, the coronavirus (COVID-19) and the effects of the outbreak and actions taken in connection therewith, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business, and those other risks and uncertainties that are described in the "Risk Factors" section of BIOLASE's most recent annual report filed on Form 10-K and quarterly report filed on Form 10-Q filed with the Securities and Exchange Commission. Except as required by law, BIOLASE does not undertake any responsibility to revise or update any forward-looking statements.

 

BIOLASE, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited, in thousands, except per share data)




Three Months Ended



Year Ended




December 31,



December 31,




2021



2020



2021



2020


Net revenue


$

12,407



$

8,520



$

39,188



$

22,780


Cost of revenue



7,501




6,915




22,659




16,607


Gross profit



4,906




1,605




16,529




6,173


Operating expenses:













  Sales and marketing



5,024




3,767




15,339




11,242


  General and administrative



2,644




2,326




11,258




9,772


  Engineering and development



1,542




1,051




6,048




3,695


  Loss on patent litigation settlement



125







315





    Total operating expenses



9,335




7,144




32,960




24,709


Loss from operations



(4,429)




(5,539)




(16,431)




(18,536)


  Gain (Loss) on foreign currency transactions



(280)




47




(452)




(21)


  Interest expense, net



(498)




(577)




(2,224)




(2,359)


  Gain on debt forgiveness









3,014





  Other income, net






6







4,215


Non-operating gain (loss), net



(778)




(524)




338




1,835


Loss before income tax provision



(5,207)




(6,063)




(16,093)




(16,701)


Income tax provision



(72)




(79)




(65)




(128)


Net loss



(5,279)




(6,142)




(16,158)




(16,829)















Net loss


$

(5,279)



$

(6,142)



$

(16,158)



$

(16,829)


Deemed dividend on convertible preferred stock









(546)




(17,378)


Net loss attributable to common stockholders


$

(5,279)



$

(6,142)



$

(16,704)



$

(34,207)















Net loss per share attributable to common stockholders:













  Basic and Diluted


$

(0.03)



$

(0.07)



$

(0.11)



$

(0.56)


Shares used in the calculation of net loss per share:













  Basic and Diluted



153,491




93,211




147,746




61,136


 

BIOLASE, INC.

CONSOLIDATED BALANCE SHEETS

(Unaudited, in thousands, except per share data)




December 31,




2021



2020


ASSETS







Current assets:







  Cash and cash equivalents


$

29,972



$

17,564


  Restricted cash



203




312


  Accounts receivable, less allowance of $2,154 and $4,017 as of December 31, 2021 and 2020, respectively



4,238




3,059


  Inventory



12,929




11,157


  Prepaid expenses and other current assets



2,012




3,018


    Total current assets



49,354




35,110


  Property, plant, and equipment, net



1,067




782


  Goodwill



2,926




2,926


  Right of use asset



1,717




1,976


  Other assets



220




231


    Total assets


$

55,284



$

41,025


LIABILITIES AND STOCKHOLDERS' EQUITY







Current liabilities:







  Accounts payable


$

3,309



$

2,651


  Accrued liabilities



8,276




6,667


  Deferred revenue, current portion



2,259




1,905


  Term loan, net of discount







    Total current liabilities



13,844




11,223


  Deferred revenue



329




374


  Warranty accrual



521




384


  Non current term loans, net of discount



13,603




16,186


  Non current operating lease liability



1,449




1,774


  Other liabilities



330




1,056


    Total liabilities



30,076




30,997


Stockholders' equity:







  Series F Preferred stock, par value $0.001 per share



34




118


  Common stock, par value $0.001 per share



154




98


  Additional paid-in capital



293,177




261,573


  Accumulated other comprehensive loss



(623)




(385)


  Accumulated deficit



(267,534)




(251,376)


    Total stockholders' equity



25,208




10,028


    Total liabilities and stockholders' equity


$

55,284



$

41,025


 

BIOLASE, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited, in thousands)




Year Ended




December 31,




2021



2020


Cash Flows from Operating Activities:







Net loss


$

(16,158)



$

(16,829)


Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities:







  Depreciation and amortization



400




499


  Provision for bad debts



(202)




1,328


  Provision for sales returns






87


  Provision for inventory excess and obsolescence



(275)




(591)


  Inventory disposals and recoveries, net



(122)




1,300


  Amortization of discount on lines of credit



159




165


  Amortization of debt issuance costs



356




331


  Patent litigation mark-to-market



315





  Change in fair value of warrants






(5,850)


  Issuance of restricted shares



164





  Issuance costs for common stock warrants






1,641


  Stock-based compensation



1,662




3,370


  Gain on debt forgiveness



(3,014)





  Changes in operating assets and liabilities:







    Accounts receivable



(978)




4,286


    Inventory



(1,375)




(871)


    Prepaid expenses and other current assets



285




825


    Accounts payable and accrued liabilities



1,765




(2,107)


    Deferred revenue



308




(379)


  Net cash and cash equivalents used in operating activities



(16,710)




(12,795)


Cash Flows from Investing Activities:







  Purchases of property, plant, and equipment



(707)




(96)


  Net cash and cash equivalents used in investing activities



(707)




(96)


Cash Flows from Financing Activities:







  Proceeds from the issuance of common stock and June 2020 Warrants, net



14,420




6,912


  Proceeds from the issuance of Series F Convertible Preferred Stock






2,700


  Proceeds from the issuance of July 2020 Warrants






15,300


  Payments of equity offering costs



(1,135)




(1,281)


  Payment of July 2020 Warrant issuance costs






(1,640)


  Borrowings on other long-term loans






3,140


  Principal payment on term loan






(700)


  Borrowings on credit facility






3,000


  Payments of credit facility






(3,000)


  Payments of debt issuance costs



(25)




(128)


  Proceeds from the exercise of common stock warrants



16,562




46


  Proceeds from exercise of stock options



132





  Net cash and cash equivalents provided by financing activities



29,954




24,349


Effect of exchange rate changes



(238)




317


Increase in cash and cash equivalents



12,299




11,775


Cash, cash equivalents and restricted cash, beginning of year



17,876




6,101


Cash, cash equivalents and restricted cash, end of year


$

30,175



$

17,876


Supplemental cash flow disclosure:







  Cash paid for interest


$

1,771



$

1,881


  Cash received for interest


$

56



$

11


  Cash paid for income taxes


$

171



$

22


  Cash paid for operating leases


$

246



$

489


  Non-cash settlement of liability


$

510



$

151


  Non-cash right-of-use assets obtained in exchange for lease obligations


$

48



$

2,037


  Equity financing costs in accounts payable


$



$

74


  Deemed dividend on preferred stock


$

546



$

17,378


  Forgiveness of debt


$



$

10


  Receivable from warrants exercised and included in prepaid and other current assets


$

(1,498)



$

1,498


  Warrants issued in connection with debt instruments


$



$

67


Non-GAAP Financial Measures

In addition to the financial information prepared in conformity with generally accepted accounting principles in the U.S. ("GAAP"), this press release includes certain historical non-GAAP financial information. Management believes that these non-GAAP financial measures assist investors in making comparisons of period-to-period operating results and that, in some respects, these non-GAAP financial measures are more indicative of the Company's ongoing core operating performance than their GAAP equivalents.

Adjusted EBITDA is defined as net loss before interest, taxes, depreciation and amortization, allowance for doubtful accounts, loss on patent litigation settlement, stock-based and other non-cash compensation, debt forgiveness, and other income, net. Management uses Adjusted EBITDA in its evaluation of the Company's core results of operations and trends between fiscal periods and believes that these measures are important components of its internal performance measurement process. Therefore, investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. Further, the non-GAAP financial measures presented by the Company may be different from similarly named non-GAAP financial measures used by other companies.

 

BIOLASE, INC.

Reconciliation of GAAP Net Loss to Adjusted EBITDA and

GAAP Net Loss Per Share to Adjusted EBITDA Per Share

(Unaudited, in thousands, except per share data)




Three Months Ended



Year  Ended




December 31,



December 31,




2021



2020



2021



2020


GAAP net loss attributable to common stockholders


$

(5,279)



$

(6,142)



$

(16,704)



$

(34,207)


  Deemed dividend on convertible preferred stock









546




17,378


GAAP net loss


$

(5,279)



$

(6,142)



$

(16,158)



$

(16,829)


Adjustments:













  Interest expense, net



498




577




2,224




2,359


  Income tax provision



72




79




65




128


  Depreciation and amortization



116




(28)




400




499


  Change in allowance for doubtful accounts



(44)




65




(202)




1,328


  Loss on patent litigation settlement



125







315





  Stock-based and other non-cash compensation



174




1,003




1,662




3,370


  Gain on debt forgiveness









(3,014)





  Other income, net






(6)







(4,215)


Adjusted EBITDA


$

(4,338)



$

(4,452)



$

(14,708)



$

(13,360)















GAAP net loss attributable to common stockholders per share, basic and diluted


$

(0.03)



$

(0.07)



$

(0.11)



$

(0.56)


 Deemed dividend on convertible preferred stock












0.28


GAAP net loss per share, basic and diluted


$

(0.03)



$

(0.07)



$

(0.11)



$

(0.28)


Adjustments:













  Interest expense, net






0.01




0.02




0.04


  Income tax provision













  Depreciation and amortization












0.01


  Change in allowance for doubtful accounts












0.02


  Loss on patent litigation settlement













  Stock-based and other non-cash compensation






0.01




0.01




0.06


  Gain on debt forgiveness









(0.02)





  Other income, net












(0.07)


Adjusted EBITDA per share, basic and diluted


$

(0.03)



$

(0.05)



$

(0.10)



$

(0.22)


 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/biolase-reports-continued-growth-for-fourth-quarter-and-full-year-2021-301505360.html

SOURCE BIOLASE, Inc.

Copyright 2022 PR Newswire

Biolase (NASDAQ:BIOL)
Historical Stock Chart
From Jun 2022 to Jul 2022 Click Here for more Biolase Charts.
Biolase (NASDAQ:BIOL)
Historical Stock Chart
From Jul 2021 to Jul 2022 Click Here for more Biolase Charts.